Scarica l'app Stockscreener
27.12
2.77%
0.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
TG Therapeutics Faces Regulatory and Legal Challenges Amid AI Risks - AInvest
Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail
TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest
TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest
TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest
Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest
Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest
TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest
TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey
TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛
TGTX Stock Falls 14.1% Amid Market Volatility - AInvest
TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest
TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks
Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest
TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com
New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN
TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Rob - GuruFocus
TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post
TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks
TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest
Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛
Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - Investor's Business Daily
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics Q2 Revenue Up 91% - The Motley Fool
TG Therapeutics Q2 Revenue Up 91% - Nasdaq
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy - TipRanks
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends - AInvest
TG Therapeutics Plunges 15.76%—Is the Earnings Miss Just the Beginning? - AInvest
TG Therapeutics and BRIUMVI: A Deep Dive into Accelerating Revenue and Strategic Expansion in the MS Market - AInvest
Earnings call transcript: TG Therapeutics Q2 2025 misses EPS, raises revenue - Investing.com UK
TG Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize
TG Therapeutics Reports Q2 Profit, Misses Wall Street ExpectationsNews and Statistics - IndexBox
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):